ABBOTT LABORATORIES·4

Feb 3, 7:20 PM ET

MANNING JOSEPH J 4

4 · ABBOTT LABORATORIES · Filed Feb 3, 2021

Insider Transaction Report

Form 4
Period: 2021-02-01
MANNING JOSEPH J
Senior Vice President
Transactions
  • Exercise/Conversion

    Common shares without par value

    2021-02-01$38.40/sh+18,750$720,00081,561 total
  • Sale

    Common shares without par value

    2021-02-01$122.79/sh18,750$2,302,26462,811 total
  • Sale

    Common shares without par value

    2021-02-02$123.03/sh3,130$385,08459,681 total
  • Exercise/Conversion

    Option (right to buy)

    2021-02-0118,75018,750 total
    Exercise: $38.40From: 2019-02-19Exp: 2026-02-18Common Shares (18,750 underlying)
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.75 to $122.8250, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.03 to $123.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F3]Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file
  • 4
    form4-02032021_040232.xmlPrimary